Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 binding site in human brain

Robin J. Tyacke, Jim F.M. Myers, Ashwin Venkataraman, Inge Mick, Samuel Turton, Jan Passchier, Stephen M. Husbands, Eugenii A. Rabiner, Roger N. Gunn, Philip S. Murphy, Christine A. Parker, David J. Nutt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The imidazoline2 binding site (I2BS) is thought to be expressed in glia and implicated in the regulation of glial fibrillary acidic protein. A PET ligand for this target would be important for the investigation of neurodegenerative and neuroinflammatory diseases. 11C-BU99008 has previously been identified as a putative PET radioligand. Here, we present the first in vivo characterization of this PET radioligand in humans and assess its test-retest reproducibility. Methods: Fourteen healthy male volunteers underwent dynamic PET imaging with 11C-BU99008 and arterial sampling. Six subjects were used in a test-retest assessment, and 8 were used in a pharmacologic evaluation, undergoing a second or third heterologous competition scan with the mixed I2BS/α2-adrenoceptor drug idazoxan (n = 8; 20, 40, 60, and 80 mg) and the mixed irreversible monoamine oxidase type A/B inhibitor isocarboxazid (n = 4; 50 mg). Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution volume). All image processing and kinetic analyses were performed in MIAKAT. Results: Brain uptake of 11C-BU99008 was good, with reversible kinetics and a heterogeneous distribution consistent with known I2BS expression. Model selection criteria indicated that the 2-tissue-compartmentmodel was preferred. VT estimates were high in the striatum (105 ± 21 mL.cm-3), medium in the cingulate cortex (62 ± 10 mL.cm-3), and low in the cerebellum (41 ± 7 mL.cm-3). Test-retest reliability was reasonable. The uptake was dose-dependently reduced throughout the brain by pretreatment with idazoxan, with an average block across all regions of about 60% (VT, -30 mL.cm-3) at the highest dose (80 mg). The median effective dose for idazoxan was 28 mg. Uptake was not blocked by pretreatment with the monoamine oxidase inhibitor isocarboxazid. Conclusion: 11C-BU99008 in human PET studies demonstrates good brain delivery, reversible kinetics, heterogeneous distribution, specific binding signal consistent with I2BS distribution, and good test-retest reliability.

LanguageEnglish
Pages1597-1602
Number of pages6
JournalJournal of Nuclear Medicine
Volume59
Issue number10
Early online date9 Mar 2018
DOIs
StatusPublished - 1 Oct 2018

Keywords

  • C-BU99008
  • BU99008
  • IBS, positron emission tomography
  • Imidazoline binding site
  • PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Tyacke, R. J., Myers, J. F. M., Venkataraman, A., Mick, I., Turton, S., Passchier, J., ... Nutt, D. J. (2018). Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 binding site in human brain. Journal of Nuclear Medicine, 59(10), 1597-1602. https://doi.org/10.2967/jnumed.118.208009

Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 binding site in human brain. / Tyacke, Robin J.; Myers, Jim F.M.; Venkataraman, Ashwin; Mick, Inge; Turton, Samuel; Passchier, Jan; Husbands, Stephen M.; Rabiner, Eugenii A.; Gunn, Roger N.; Murphy, Philip S.; Parker, Christine A.; Nutt, David J.

In: Journal of Nuclear Medicine, Vol. 59, No. 10, 01.10.2018, p. 1597-1602.

Research output: Contribution to journalArticle

Tyacke, RJ, Myers, JFM, Venkataraman, A, Mick, I, Turton, S, Passchier, J, Husbands, SM, Rabiner, EA, Gunn, RN, Murphy, PS, Parker, CA & Nutt, DJ 2018, 'Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 binding site in human brain', Journal of Nuclear Medicine, vol. 59, no. 10, pp. 1597-1602. https://doi.org/10.2967/jnumed.118.208009
Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J et al. Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 binding site in human brain. Journal of Nuclear Medicine. 2018 Oct 1;59(10):1597-1602. https://doi.org/10.2967/jnumed.118.208009
Tyacke, Robin J. ; Myers, Jim F.M. ; Venkataraman, Ashwin ; Mick, Inge ; Turton, Samuel ; Passchier, Jan ; Husbands, Stephen M. ; Rabiner, Eugenii A. ; Gunn, Roger N. ; Murphy, Philip S. ; Parker, Christine A. ; Nutt, David J. / Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 binding site in human brain. In: Journal of Nuclear Medicine. 2018 ; Vol. 59, No. 10. pp. 1597-1602.
@article{61d2300a52384b2ba99a88b7f765f1f8,
title = "Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 binding site in human brain",
abstract = "The imidazoline2 binding site (I2BS) is thought to be expressed in glia and implicated in the regulation of glial fibrillary acidic protein. A PET ligand for this target would be important for the investigation of neurodegenerative and neuroinflammatory diseases. 11C-BU99008 has previously been identified as a putative PET radioligand. Here, we present the first in vivo characterization of this PET radioligand in humans and assess its test-retest reproducibility. Methods: Fourteen healthy male volunteers underwent dynamic PET imaging with 11C-BU99008 and arterial sampling. Six subjects were used in a test-retest assessment, and 8 were used in a pharmacologic evaluation, undergoing a second or third heterologous competition scan with the mixed I2BS/α2-adrenoceptor drug idazoxan (n = 8; 20, 40, 60, and 80 mg) and the mixed irreversible monoamine oxidase type A/B inhibitor isocarboxazid (n = 4; 50 mg). Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution volume). All image processing and kinetic analyses were performed in MIAKAT. Results: Brain uptake of 11C-BU99008 was good, with reversible kinetics and a heterogeneous distribution consistent with known I2BS expression. Model selection criteria indicated that the 2-tissue-compartmentmodel was preferred. VT estimates were high in the striatum (105 ± 21 mL.cm-3), medium in the cingulate cortex (62 ± 10 mL.cm-3), and low in the cerebellum (41 ± 7 mL.cm-3). Test-retest reliability was reasonable. The uptake was dose-dependently reduced throughout the brain by pretreatment with idazoxan, with an average block across all regions of about 60{\%} (VT, -30 mL.cm-3) at the highest dose (80 mg). The median effective dose for idazoxan was 28 mg. Uptake was not blocked by pretreatment with the monoamine oxidase inhibitor isocarboxazid. Conclusion: 11C-BU99008 in human PET studies demonstrates good brain delivery, reversible kinetics, heterogeneous distribution, specific binding signal consistent with I2BS distribution, and good test-retest reliability.",
keywords = "C-BU99008, BU99008, IBS, positron emission tomography, Imidazoline binding site, PET",
author = "Tyacke, {Robin J.} and Myers, {Jim F.M.} and Ashwin Venkataraman and Inge Mick and Samuel Turton and Jan Passchier and Husbands, {Stephen M.} and Rabiner, {Eugenii A.} and Gunn, {Roger N.} and Murphy, {Philip S.} and Parker, {Christine A.} and Nutt, {David J.}",
year = "2018",
month = "10",
day = "1",
doi = "10.2967/jnumed.118.208009",
language = "English",
volume = "59",
pages = "1597--1602",
journal = "The Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "10",

}

TY - JOUR

T1 - Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 binding site in human brain

AU - Tyacke, Robin J.

AU - Myers, Jim F.M.

AU - Venkataraman, Ashwin

AU - Mick, Inge

AU - Turton, Samuel

AU - Passchier, Jan

AU - Husbands, Stephen M.

AU - Rabiner, Eugenii A.

AU - Gunn, Roger N.

AU - Murphy, Philip S.

AU - Parker, Christine A.

AU - Nutt, David J.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The imidazoline2 binding site (I2BS) is thought to be expressed in glia and implicated in the regulation of glial fibrillary acidic protein. A PET ligand for this target would be important for the investigation of neurodegenerative and neuroinflammatory diseases. 11C-BU99008 has previously been identified as a putative PET radioligand. Here, we present the first in vivo characterization of this PET radioligand in humans and assess its test-retest reproducibility. Methods: Fourteen healthy male volunteers underwent dynamic PET imaging with 11C-BU99008 and arterial sampling. Six subjects were used in a test-retest assessment, and 8 were used in a pharmacologic evaluation, undergoing a second or third heterologous competition scan with the mixed I2BS/α2-adrenoceptor drug idazoxan (n = 8; 20, 40, 60, and 80 mg) and the mixed irreversible monoamine oxidase type A/B inhibitor isocarboxazid (n = 4; 50 mg). Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution volume). All image processing and kinetic analyses were performed in MIAKAT. Results: Brain uptake of 11C-BU99008 was good, with reversible kinetics and a heterogeneous distribution consistent with known I2BS expression. Model selection criteria indicated that the 2-tissue-compartmentmodel was preferred. VT estimates were high in the striatum (105 ± 21 mL.cm-3), medium in the cingulate cortex (62 ± 10 mL.cm-3), and low in the cerebellum (41 ± 7 mL.cm-3). Test-retest reliability was reasonable. The uptake was dose-dependently reduced throughout the brain by pretreatment with idazoxan, with an average block across all regions of about 60% (VT, -30 mL.cm-3) at the highest dose (80 mg). The median effective dose for idazoxan was 28 mg. Uptake was not blocked by pretreatment with the monoamine oxidase inhibitor isocarboxazid. Conclusion: 11C-BU99008 in human PET studies demonstrates good brain delivery, reversible kinetics, heterogeneous distribution, specific binding signal consistent with I2BS distribution, and good test-retest reliability.

AB - The imidazoline2 binding site (I2BS) is thought to be expressed in glia and implicated in the regulation of glial fibrillary acidic protein. A PET ligand for this target would be important for the investigation of neurodegenerative and neuroinflammatory diseases. 11C-BU99008 has previously been identified as a putative PET radioligand. Here, we present the first in vivo characterization of this PET radioligand in humans and assess its test-retest reproducibility. Methods: Fourteen healthy male volunteers underwent dynamic PET imaging with 11C-BU99008 and arterial sampling. Six subjects were used in a test-retest assessment, and 8 were used in a pharmacologic evaluation, undergoing a second or third heterologous competition scan with the mixed I2BS/α2-adrenoceptor drug idazoxan (n = 8; 20, 40, 60, and 80 mg) and the mixed irreversible monoamine oxidase type A/B inhibitor isocarboxazid (n = 4; 50 mg). Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution volume). All image processing and kinetic analyses were performed in MIAKAT. Results: Brain uptake of 11C-BU99008 was good, with reversible kinetics and a heterogeneous distribution consistent with known I2BS expression. Model selection criteria indicated that the 2-tissue-compartmentmodel was preferred. VT estimates were high in the striatum (105 ± 21 mL.cm-3), medium in the cingulate cortex (62 ± 10 mL.cm-3), and low in the cerebellum (41 ± 7 mL.cm-3). Test-retest reliability was reasonable. The uptake was dose-dependently reduced throughout the brain by pretreatment with idazoxan, with an average block across all regions of about 60% (VT, -30 mL.cm-3) at the highest dose (80 mg). The median effective dose for idazoxan was 28 mg. Uptake was not blocked by pretreatment with the monoamine oxidase inhibitor isocarboxazid. Conclusion: 11C-BU99008 in human PET studies demonstrates good brain delivery, reversible kinetics, heterogeneous distribution, specific binding signal consistent with I2BS distribution, and good test-retest reliability.

KW - C-BU99008

KW - BU99008

KW - IBS, positron emission tomography

KW - Imidazoline binding site

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=85054063792&partnerID=8YFLogxK

U2 - 10.2967/jnumed.118.208009

DO - 10.2967/jnumed.118.208009

M3 - Article

VL - 59

SP - 1597

EP - 1602

JO - The Journal of Nuclear Medicine

T2 - The Journal of Nuclear Medicine

JF - The Journal of Nuclear Medicine

SN - 0161-5505

IS - 10

ER -